TGF-β1 production in radiation nephropathy: Role of angiotensin II

International Journal of Radiation Biology

Volumn 75, Issue 4, 1999, Pages 473-479

  Datta, P K ^a   Moulder, J E ^a   Fish, B L ^a   Cohen, E P ^a   Lianos, E A ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SCREENING; FEMALE; GLOMERULUS; HISTOPATHOLOGY; KIDNEY DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RADIATION EXPOSURE; RADIATION INJURY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UREA NITROGEN BLOOD LEVEL;

ANIMALIA; GLOMERULUS;

EID: 0005643560     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530099140401     Document Type: Article

References (58)

1. Anscher, M. S., Kong, F. M. and Jirtle, R. L., 1998, The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer, 19, 109-120.
2. Barcellos-Hoff, M. H., 1993, Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary-gland. Cancer Research, 53, 3880-3886.
3. Barcellos-Hoff, M. H., Derynck, R., Tsang, M. L. and Weatherbee, J. A., 1994, Transforming growth factor-β activation in irradiated murine mammary gland. Journal of Clinical Investigation, 93, 892-899.
4. Barcellos-Hoff, M. H. and Dix, T. A., 1996, Redoz-mediated activation of latent transforming growth factor-β1. Molecular Endocrinology, 10, 1077-1083.
5. Border, W. A. and Noble, N. A., 1994, Transforming growth factor-β in tissue fibrosis. New England Journal of Medicine, 331, 1286-1292.
6. Chang, R. S. L., Siegl, P. K. S., Clineschmidt, B. V., Mantlo, N. B., Chakravarty, P. K., Greenlee, W. J., Patchett, A. A. and Lotti, V. J., 1992, In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 262, 133-138.
7. Cohen, E. P., Fish, B. L. and Moulder, J. E., 1992, Treatment of radiation nephropathy with captopril. Radiation Research, 132, 346-350.
8. Cohen, E. P., Fish, B. L. and Moulder, J. E., 1997, Successful brief captopril treatment in experimental radiation nephropathy. Journal of Laboratory and Clinical Medicine, 129, 536-547.
9. Cohen, E. P., Fish, B. L. and Moulder, J. E., 1998, Timed angiotensin II infusion exacerbates radiation nephropathy via arteriolar injury. Journal of the American Society of Nephrology, 9, 492a.
10. Cohen, E. P., Molteni, A., Hill, P., Fish, B. L., Ward, W. F., Moulder, J. E. and Carone, F. A., 1996, Captopril preserves function and infrastructure in experimental radiation nephropathy. Laboratory Investigation, 75, 349-360.
11. Cohen, E. P., Moulder, J. E., Fish, B. L. and Hill, P., 1994, Prophylaxis of experimental bone marrow transplant nephropathy. Journal of Laboratory and Clinical Medicine, 124, 371-380.
12. Das, S. K., White, A. C. and Fanburg, B. L., 1992, Modulation of transforming growth factor β-1 antiproliferative effects on endothelial cells by cysteine, cystine and N-acetylcysteine. Journal of Clinical Investigation, 90, 1649-1656.
13. Finkelstein, J. N., Johnston, C. J., Baggs, R. and Rubin, P., 1994, Early alterations in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis. International Journal of Radiation Oncology, Biology, Physics, 28, 621-631.
14. Flaumenhaft, R., Abe, M., Sato, Y., Miyazono, K., Harpel, J., Heldin, C. H. and Rifkin, D. B., 1993, Role of the latent TGF-β binding protein in the activation of latent TGF-β by co-cultures of endothelial and smooth muscle cells. Journal of Cell Biology, 120, 995-1002.
15. Gentry, L. E. and Nash, B. W., 1990, The pro domain of pre-pro-transforming growth factor β1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry, 29, 6851-6857.
16. Ichikawa, I. and Harris, R. C., 1991, Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney International, 40, 583-596.
17. Ishidoya, S., Morrissey, J., McCracken, R. and Klahr, S., 1996, Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney International, 49, 1110-1119.
18. Islam, K. N., Kayanoki, Y., Kaneto, H., Suzuki, K., Asahi, M., Fujii, J. and Taniguchi, N., 1997, TGF-β1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radical Biology and Medicine, 22, 1007-1017.
19. Itoh, H., Mukoyama, M., Pratt, R. E., Gibbons, G. H. and Dzau, V. J., 1993, Multiple autocrine growth factors modulate vascular smooth muscle cell growth responses to angiotensin II. Journal of Clinical Investigation, 91, 2268-2274.
20. Johnston, C. I., 1995, Angiotensin receptor antagonists: focus on losartan. Lancet, 346, 1403-1407.
21. Juncos, L. I., Carrasco Dueñas, S., Cornejo, J. C., Broglia, C. A. and Cejas, H., 1993, Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron, 64, 249-255.
22. Kagami, S., Border, W. A., Miller, D. E. and Noble, N. A., 1994, Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. Journal of Clinical Investigation, 93, 2431-2437.
23. Kanzaki, T., Olofsson, A., Moren, A., Wernstedt, C., Hellman, U., Miyazono, K., Claesson-Welsh, L. and Heldin, C. H., 1990, TGF-β1 binding protein: a component of the large latent complex of TGF-β1 with multiple repeat sequences. Cell, 61, 1051-1061.
24. Kayanoki, Y., Fujii, J., Suzuki, K., Kawata, S., Matsuzawa, Y. and Taniguchi, N., 1994, Suppression of antioxidative enzyme expression by transforming growth factor-β1 in rat hepatocytes. Journal of Biological Chemistry, 269, 15488-15492.
25. Kraft, M., Oussoren, Y., Stewart, F. A., Dorr, W. and Schultz-Hector, S., 1996, Radiation-induced changes in transforming growth factor β and collagen expression in the murine bladder wall and its correlation with bladder function. Radiation Research, 146, 619-627.
26. Langer, C., Jurgensmeier, J. M. and Bauer, G., 1996, Reactive oxygen species act at both TGF-β-dependent and -independent steps during induction of apoptosis of transformed cells by normal cells. Experimental Cell Research, 222, 117-124.
27. Lianos, E. A., 1988, Synthesis of hydroxyeicosatetraenoic acids and leukotrienes in rat nephrotoxic serum glomerulo-nephritis. Role of anti-glomerular basement membrane antibody dose, complement, and neutrophiles. Journal of Clinical Investigation, 82, 427-435.
28. Lyons, R. M., Gentry, L. E., Purchio, A. F. and Moses, H. L., 1990, Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. Journal of Cell Biology, 110, 1361-1367.
29. Miyazono, K. and Heldin, C. H., 1989, Role for carbohydrate structures in TGF-β1 latency. Nature, 338, 158-160.
30. Miyazono, K., Hellman, U., Wernstedt, C. and Heldin, C. H., 1988, Latent high molecular weight complex of transforming growth factor β1. Purification from human platelets and structural characterization. Journal of Biological Chemistry, 263, 6407-6415.
31. Moulder, J. E. and Fish, B. L., 1989, Late toxicity of total body irradiation with bone marrow transplantation in a rat model. International Journal of Radiation Oncology, Biology, Physics, 16, 1501-1509.
32. Moulder, J. E. and Fish, B. L., 1997, Age dependence of radiation nephropathy in the rat. Radiation Research, 147, 349-353.
33. Moulder, J. E., Fish, B. L. and Cohen, E. P., 1993, Treatment of radiation nephropathy with ACE inhibitors. International Journal of Radiation Oncology, Biology, Physics, 27, 93-99.
34. Moulder, J. E., Fish, B. L. and Cohen, E. P., 1998a, Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. International Journal of Radiation Biology, 73, 415-421.
35. Moulder, J. E., Fish, B. L. and Cohen, E. P., 1998b, Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (ATI) receptor antagonist. Radiotherapy and Oncology, 46, 307-315.
36. Moulder, J. E., Fish, B. L. and Cohen, E. P., 1998d, Brief pharmacologic intervention in experimental radiation nephropathy. Radiation Research, 73, 415-421.
37. Moulder, J. E., Fish, B. L., Cohen, E. P. and Bonsib, S. M., 1996, Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiation Research, 146, 106-110.
38. Moulder, J. E., Robbins, M. E. C., Cohen, E. P., Hopewell, J. W. and Ward, W. F., 1998c, Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treatment and Research, 93, 129-151.
39. Noble, N. A. and Border, W. A., 1997, Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the therapeutic target? Seminars in Nephrology, 17, 455-466.
40. Ohba, M., Shibanuma, M., Kuroki, T. and Nose, K., 1994, Production of hydrogen peroxide by transforming growth factor-β1 and its involvement in induction of egr-1 in mouse osteoblastic cells. Journal of Cell Biology, 126, 1079-1088.
41. Ohta, K., Kim, S., Hamaguchi, A., Yukimura, T., Miura, K., Takaori, K. and Iwao, H., 1994, Role of angiotensin II in extracellular matrix and transforming growth factor-β1 expression in hypertensive rats. European Journal of Pharmacology, 269, 115-119.
42. Oikawa, T., Freeman, M., Wilbur, L., Vaughan, D. E. and Fogo, A., 1997, Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney International, 51, 164-172.
43. Okada, F., Yamaguchi, K., Ichihara, A. and Nakamura, T., 1989, Purification and structural analysis of a latent form of transforming growth factor-β from rat platelets. Journal of Biochemistry, 106, 304-310.
44. Pimentel, J. L., Sundell, C. L., Wang, S., Kopp, J. B., Montero, A. and Martinez-Maldonado, M., 1995, Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney International, 48, 1233-1246.
45. Randall, K. and Coggle, J. E., 1995, Expression of transforming growth factor-β1 in mouse skin during the acute phase of radiation damage. International Journal of Radiation Biology, 68, 301-309.
46. Robbins, M. E. C. and Bonsib, S. M., 1995, Radiation nephropathy: a review. Scanning Electron Microscopy, 9, 535-560.
47. Ruiz-Ortega, M., Gonzalez, S., Seron, D., Condom, E., Bustos, C., Largo, R., Gonzalez, E., Ortiz, A. and Egido, J., 1995, ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis, Kidney International, 48, 1778-1791.
48. Sanchez, A., Alvarez, A. M., Benito, M. and Fabregat, I., 1996, Apoptosis induced by transforming growth factor-β in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. Journal of Biological Chemistry, 271, 7416-7422.
49. Schultz-Cherry, S. and Murphy-Ullrich, J. E., 1993, Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. Journal of Cell Biology, 122, 923-932.
50. 2 and phosphorylation of 30 kilodalton proteins as early responses of cell cycle-dependent inhibition of DNA synthesis by transforming growth factor β1. Cell Growth and Differentation, 2, 583-591.
51. Shihab, F. S., Bennett, W. M., Tanner, A. M. and Andoh, T. K., 1997, Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney International, 52, 660-673.
52. Siegel, P. K. S., Chang, R. S. L., Mantlo, N. B., Chakravarty, P. K., Ondeyka, D. L., Greenlee, W. J., Pattchett, A. A., Sweet, C. S. and Lotti, V. J., 1992, In vivo pharmacology of L-158,809, a new highly potent and selective non-peptide angiotensin II receptor blocker. Journal of Pharmacology and Experimental Therapeutics, 262, 139-144.
53. Taipale, J., Miyazono, K., Heldin, C. H. and Keski-Oja, J., 1994, Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. Journal of Cell Biology, 124, 171-181.
54. 2-generating NADH oxidase in human lung fibroblasts by transforming growth factor β1. Journal of Biological Chemistry, 270, 30334-30338.
55. 2 release from bovine pulmonary artery endothelial cells induced by TGF-β1. American Journal of Physiology, 265, L622-L626.
56. Tsuji, T., Okada, F., Yamaguchi, K. A. and Nakamura, T., 1990, Molecular cloning of the large subunit of transforming growth factor type β masking protein and expression of the mRNA in various rat tissues. Proceeding of the National Academy of Sciences, U S A, 87, 8835-8839.
57. Wang, J. and Robbins, M. E. C., 1996, Radiation-induced alteration of rat mesangial cell transforming growth factor-β and expression of the genes associated with the extracellular matrix. Radiation Research, 146, 561-568.
58. Wolf, G. and Neilson, E. G., 1993, Angiotensin II as a renal growth factor. Journal of the American Society of Nephrology, 3, 1532-1540.